Safety and Efficacy of Autologous iNSC-DAP in the Treatment of Parkinson's Disease
Status:
Recruiting
Trial end date:
2026-12-31
Target enrollment:
Participant gender:
Summary
This is a phase I, interventional, single arm, open-label, clinical study to evaluate the
safety and efficacy of the striatal transplantation of autologous induced neural stem
cell-derived DA precursor cells in Parkinson's Disease patients.